Effect of the direction of MICA mismatches on relevant clinical outcomes
| . | All mismatches (n = 113) . | GvH mismatches (n = 11) . | HvG mismatches (n = 17) . | Bidirectional mismatches (n = 85) . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Acute GVHD III-IV | 1.83 (1.50-2.23) | <.001 | 1.64 (1.39-1.93) | <.001 | 1.86 (1.18-2.93) | .008 | 1.78 (1.45-2.19) | <.001 |
| Chronic GVHD | 1.50 (1.45-1.55) | <.001 | 1.60 (1.08-2.37) | .019 | 1.83 (0.80-4.15) | .150 | 1.38 (1.12-1.70) | .002 |
| Relapse* | 0.50 (0.43-0.59) | <.001 | 0.49 (0.38-0.62) | <.001 | 0.99 (0.66-1.47) | .96 | 0.46 (0.34-0.61) | <.001 |
| Overall survival | 1.02 (0.91-1.14) | .70 | 1.63 (1.09-2.43) | .017 | 0.62 (0.40-0.96) | .033 | 0.99 (0.88-1.11) | .864 |
| Relapse-free survival | 0.97 (0.81-1.16) | .75 | 1.40 (0.97-2.02) | .075 | 1.02 (0.66-1.56) | .944 | 0.85 (0.69-1.06) | .145 |
| Nonrelapse mortality | 1.35 (1.24-1.46) | <.001 | 2.18 (1.41-3.37) | <.001 | 1.07 (0.97-1.18) | .151 | 1.19 (1.05-1.34) | .005 |
| . | All mismatches (n = 113) . | GvH mismatches (n = 11) . | HvG mismatches (n = 17) . | Bidirectional mismatches (n = 85) . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Acute GVHD III-IV | 1.83 (1.50-2.23) | <.001 | 1.64 (1.39-1.93) | <.001 | 1.86 (1.18-2.93) | .008 | 1.78 (1.45-2.19) | <.001 |
| Chronic GVHD | 1.50 (1.45-1.55) | <.001 | 1.60 (1.08-2.37) | .019 | 1.83 (0.80-4.15) | .150 | 1.38 (1.12-1.70) | .002 |
| Relapse* | 0.50 (0.43-0.59) | <.001 | 0.49 (0.38-0.62) | <.001 | 0.99 (0.66-1.47) | .96 | 0.46 (0.34-0.61) | <.001 |
| Overall survival | 1.02 (0.91-1.14) | .70 | 1.63 (1.09-2.43) | .017 | 0.62 (0.40-0.96) | .033 | 0.99 (0.88-1.11) | .864 |
| Relapse-free survival | 0.97 (0.81-1.16) | .75 | 1.40 (0.97-2.02) | .075 | 1.02 (0.66-1.56) | .944 | 0.85 (0.69-1.06) | .145 |
| Nonrelapse mortality | 1.35 (1.24-1.46) | <.001 | 2.18 (1.41-3.37) | <.001 | 1.07 (0.97-1.18) | .151 | 1.19 (1.05-1.34) | .005 |
N represents the number of mismatched patients considered. Results are presented as HRs with 95% CIs. All models were performed separately and were adjusted for patient’s age, patient–donor sex, patient–donor serological status for cytomegalovirus, year of transplantation, time to transplantation, transplantation center, source of stem cells, conditioning regimen, GVHD prophylaxis, treatment with antithymocyte globulin or Alemtuzumab, HLA-DPB1 matching status, disease category, and severity at transplantation.
Transplantations done for nonmalignant diseases were excluded from this analysis.